Catalent (CTLT) Stock Price
Catalent Price
Over the last 15 years Catalent grew revenue by 7.9% annually, reaching 4.38 B USD. Earnings per share have grown at 46.7% per year over the last 8 years. For Catalent, the net margin of -23.8% is down versus 5.6% a few years ago. The consensus 12-month price target for Catalent is 64.77 USD, about 2.0% above where the stock trades today. Of 14 analysts, 0 rate the stock a buy — an overall Hold consensus.
Catalent stock price
Catalent business model & stock analysis
Frequently asked questions about Catalent
Catalent Inc is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With its strategic approach, Catalent offers a broad range of integrated services to ensure efficient drug development and delivery. The company's business model focuses on collaborating with pharmaceutical and biotechnology companies to accelerate their product development process and bring innovative therapies to market. By leveraging its expertise in formulation and development, advanced delivery systems, and manufacturing solutions, Catalent helps its clients optimize their chances of success while delivering high-quality products to patients worldwide.
Catalent Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Catalent Inc in the market include Thermo Fisher Scientific Inc, Lonza Group Ltd, and Patheon N.V.
Catalent Inc is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With a rich history spanning over 80 years, Catalent has established itself as a trusted partner to pharmaceutical and biotech companies worldwide. The company was founded in 2007 through the merger of RP Scherer Corporation and Cardinal Health's pharmaceutical technologies and services segment. Catalent Inc has continuously evolved and expanded its capabilities, offering a wide range of solutions including drug development, manufacturing, packaging, and supply chain services. Today, Catalent Inc is recognized for its innovative approach, cutting-edge technologies, and commitment to delivering exceptional customer value in the healthcare industry.
Catalent Inc, a leading global provider of advanced delivery technologies and development solutions, has achieved numerous significant milestones over the years. One notable achievement is its successful acquisition of Cook Pharmica LLC, which expanded its biologics development and manufacturing capabilities. Additionally, the company has strengthened its global presence by opening new facilities in strategic locations, such as a state-of-the-art biomanufacturing facility in Bloomington, Indiana. Catalent Inc has also received various awards and recognition for its innovation, including being named the Contract Development and Manufacturing Organization of the Year by Pharma Integrates. These milestones highlight Catalent Inc's commitment to growth, innovation, and delivering advanced solutions to its customers.
Catalent Inc is primarily present in multiple countries and regions. With a global presence, this innovative company operates in North America, Europe, Asia Pacific, and Latin America. Catalent Inc has established manufacturing, development, and distribution facilities in various locations across the United States, including New Jersey, Indiana, and Maryland. In Europe, the company operates in multiple countries, including the United Kingdom, Germany, and Italy. In the Asia Pacific region, Catalent Inc has a strong presence in China, Singapore, and Japan. Additionally, the company has operations in Brazil, Argentina, and Mexico, among other countries in Latin America.
Catalent Inc represents key values of innovation, collaboration, and customer focus. With a corporate philosophy centered on driving exceptional experiences and outcomes for patients and customers, Catalent is committed to delivering advanced solutions for the development and manufacturing of pharmaceutical products. The company's dedication to scientific excellence and quality ensures the precise delivery and reliable supply of medicines to improve health globally. Catalent's strong expertise in drug delivery technologies, development solutions, and manufacturing capabilities positions them as a trusted partner in the pharmaceutical industry. Emphasizing continuous improvement and sustainable practices, Catalent Inc remains dedicated to making a meaningful impact in healthcare.
Analysts currently set an average price target of 64.77 USD for the Catalent stock (median: 64.77 USD), implying +2.0 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Catalent stock: 0 recommend buying, 11 holding and 3 selling. For 2026, analysts expect Catalent to generate revenue of 5.00 B USD and earnings per share of 1.75 USD.
Converted at the current exchange rate, the Catalent share trades at 55.70 EUR (63.48 USD).
The Catalent share (CTLT) is listed on 4 stock exchanges, including: NYSE (CTLT), SIX (Zürich) (0C8.SW), Frankfurt (0C8.F), München (0C8.MU).
Catalent Inc. is a globally operating company that focuses on the development and manufacturing of pharmaceuticals, as well as supporting biotech and pharmaceutical companies. It operates in three business segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. These segments offer a variety of products and services tailored to the different needs of biotech and pharmaceutical companies. Catalent Inc. earns revenue through the sale of its products and services, as well as partnerships and collaborations with other companies. It works closely with its customers to develop customized solutions and achieve a high level of customer satisfaction.
The expected revenue of Catalent is 5.00 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Catalent is 318.65 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Catalent is currently 36.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Catalent stock.
The price-to-sales ratio (P/S) of Catalent is currently 2.31. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Catalent stock.
The Eulerpool Quality Score for Catalent is 2/10.
The ISIN of Catalent is US1488061029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Catalent is A112H2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Catalent is CTLT. The ticker symbol is used to trade Catalent shares on the stock exchange.
Catalent paid dividends every year for the past 0 years.
Catalent is assigned to the 'Health' sector.
The dividends of Catalent are distributed in USD.
Catalent stock
Catalent Peer Group
Catalent Ticker
Catalent FIGI
All fundamentals and in-depth analysis of Catalent
Our stock analysis for Catalent stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Catalent. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.